Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer

Di Wang, Huijun Zhu, Qing Ye, Chenyi Wang, and Yunzhao Xu

Abstract: Kinesin family member 2A (KIF2A) is a member of Kinesin-13 family and involved in cell migration and cell signaling. Human epidermal growth factor receptor 2 (HER2-neu) is implicated in the development of many cancers. Both of these 2 proteins are upstream inducer of PI3K/AKT signaling pathway that plays an important role in the regulation of many cellular events including proliferation, survival, and invasion. We hypothesized that aberrant KIF2A and HER2-neu expression might be associated with aggressive behavior of epithelial ovarian cancer (EOC).

To address the prognostic implications of KIF2A and HER2-neu in EOC, we assessed protein levels of KIF2A and HER2-neu in 159 ovarian and fallopian tube tissues (111 carcinomas and 48 normal ovary or fallopian tube tissues) by immunohistochemistry (IHC) analysis on tissue microarray and KIF2A mRNA levels in 35 ovarian and fallopian tube tissues (15 carcinomas and 20 normal ovary or fallopian tube tissues) by real-time PCR.

We found that significantly higher KIF2A mRNA expression in EOC tumors than that in normal ovary or fallopian tube tissues. The IHC results showed that protein of KIF2A and HER2-neu was overexpressed in EOC tissues compared with normal ovary or fallopian tube tissues, and KIF2A expression level was significantly associated with lymph nodes, metastasis, ascites, cells, and FIGO stage. No correlation between KIF2A and HER2-neu expression was observed. Survival analysis showed that patients with KIF2A and HER2-neu overexpression had a worse overall survival (OS) as compared to patients with low or none expression of the 2 proteins. Multivariate analysis of variance revealed that overexpression of KIF2A was an independent prognostic factor for OS.

These findings indicate the important role of KIF2A in predicting EOC prognosis.

Abbreviations: EOC = epithelial ovarian cancer, HER2-neu = human epidermal growth factor receptor 2, KIF2A = Kinesin family member 2A, OS = overall survival, TMA = tissue microarray.

INTRODUCTION

Ovarian cancer is the deadliest gynecologic malignancies. Approximately more than 204,000 new ovarian cancer cases and 125,000 deaths occur yearly, constituting 4% of entire cancer cases and 4.2% of cancer deaths in women worldwide. Despite the fact that average survival time has been prolonged slightly over the past decades, 5-year survival rate for ovarian cancer remains under 50%. The poor prognosis is largely attributed to the poor understanding of the events that initiate ovarian cancer and promote the disease to progress. Biomarkers have been shown to play a critical role in the era of big data-driven personalized medicine, since they have greatly enhanced early cancer detection rate and help to ameliorate the clinical outcomes. Given the exceptional poor diagnosis of ovarian cancer, there is an urgent need to discover novel biomarkers with high sensitivity and specificity for the early diagnosis and targeted therapies of this disease.

Kinesin family member 2A (KIF2A) is a member of Kinesin-13 family. Human homolog of KIF2A is a motor protein engaged in transporting cargo proteins along microtubules, which specifically localizes to centrosomes during mitosis. It was reported that KIF2A silencing induced tumor cell apoptosis in vitro partially by suppressing the PI3K/AKT signaling pathway, a pathway commonly overactivated in a wide spectrum of human cancers. Another important protein-related PI3K/AKT pathway is human epidermal growth factor receptor 2 (HER2-neu, alias: ERBB2), which is implicated in carcinogenesis of various cancer types, including ovarian cancer. HER2-neu is a tyrosine kinase receptor in the epidermal growth factor family and plays an important role in cell proliferation and tumor cell metastasis. The PI3K/AKT pathway is a major downstream signaling pathway of HER2-neu.

Amplification and overexpression of HER2-neu has been detected in up to 15% of breast cancers and in 7% to 20% of gastric cancers, which appeared to be a predictor of poor prognosis for cancer. Either gene amplification or overexpression may result in the dysregulation of HER2 signaling in epithelial ovarian cancer (EOC), thereby leading to excessive cell growth, DNA damage, and accelerating tumor progression. Taken together, these findings suggested that both KIF2A and HER2-neu might contribute to cancer progression, metastasis, and poor clinical outcomes partially through activating the PI3K/AKT signaling pathway.

So far, the relationship between KIF2A protein expression and clinical parameters in EOC has not been assessed. Moreover, prognostic values of combined KIF2A and HER2-neu remain unclear. Therefore, in this study, we aimed to determine expression levels of both HER2-neu and KIF2A protein in...
ovarian epithelial tumor samples and to analyze the correlation between KIF2A, HER2-neu, and other clinicopathological features in a cohort of EOC patients.

MATERIALS AND METHODS

Human Tissue Specimens and Patient Clinical Information

A total of 159 formalin-fixed paraffin-embedded tissue samples were included in this study, comprising 24 normal ovarian, 24 normal fallopian tube, and 111 EOC samples. EOC samples obtained from patients diagnosed with ovarian carcinoma who underwent initial surgery at the Gynecology Department of Nantong University Affiliated Hospital from 2005 to 2009 were fixed in formalin and embedded in paraffin. The tissue samples with informed consent from patients were obtained at the time of surgery in the Department of Gynecology, Nantong University Affiliated Hospital. In order to achieve a maximal tumor resection, all ECO patients received standard operation and a platinum-based chemotherapy for at least 6 cycles after resection. None of the patients received any therapy against carcinoma prior to the surgical operation. Clinical information of the patients’ was recorded in detail, and the diagnoses were confirmed by at least 2 pathologists. Of the 111 ovarian cancer cases, 84 were serous carcinoma, and 27 cases were other types. There were 51 cases in stage I, 16 cases in stage II, 42 cases in stage III, and 2 cases in stage IV. With regard to histological grading, 90 cases were in high grade and 21 cases were in low grade. The average age of patients (24–78 years) was 51.26 ± 14.75 years. All patients were followed up from surgery through December 31, 2014. Besides, another 15 carcinoma samples and 20 normal ovary or fallopian tube tissue samples were collected for real-time PCR analysis. The present study was approved by the Ethics Committee of Nantong University Affiliated Hospital.

RNA Isolation and Quantification of Transcript Levels

The total RNA was isolated according to the protocol of TRIZOL reagent (Life Technologies). The LightCycler FastStart DNA Master SYBR Green I Kit (Roche Diagnostics, Tokyo, Japan) was used to carry out real-time PCR, following previously published procedure. Primers for KIF2A were as follows, forward primer 5′-AGAGTATACTACATCAAGC-3′ and reverse primer 5′-CTCTCCAGGTCAATCTCTT-3′. Moreover, the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was as follows, forward primer 5′-GGCATGGACTGTGGTCATGAG-3′ and reverse primer 3′-GCCGAATACATCAAGCAAT-5′. To normalize KIF2A gene expression. Specific ways of reverse transcription and amplification were described by Fan et al.

Tissue Microarray Construction and Immunohistochemistry (IHC) Analysis

The experimental methods of tissue microarray construction in details were performed as previously described by using tissue microarray system (Quick-Ray, UT06, UNITMA, Korea). KIF2A was detected by mouse monoclonal anti-KIF2A antibody (dilution 1:100) (Abcam, ab55383). HER2-neu was detected by rabbit anti-human HER2-neu antibody (dilution 1:50) (Dako, A0485). Not knowing about the clinical characteristics, 2 independent pathologists reviewed and scored the staining intensity of KIF2A and HER2-neu of each slide.

Staining intensity, percentage of positive cells, and the product of the percentage and intensity score were described previously. We used the X-tile software program (The Rimm Lab at Yale University; http://www.tissuerealarray.com/rimmlab) to set the cutoff point that was statistically significant in terms of overall survival which described previously. For KIF2A and HER2-neu expression score, we used the cutoff 120 to assess as follows: 0 to 120: low expression and 121 to 300: high expression. For all subsequent analyses, KIF2A and HER2-neu protein expression levels were considered either as “Low” or “High” using these cutoff values.

Statistical Analysis

Statistical calculations of KIF2A mRNA expression were performed using t test. Chi-squared tests were used to evaluate whether KIF2A expression alone or combined with HER2-neu was correlated with clinicopathological factors of EOC. Patient survival curves were plotted using the Kaplan–Meier method. We adopted univariate and multivariate Cox regression models to evaluate prognostic significance. Data were analyzed using SPSS 20 statistics software (SPSS Inc., Chicago, IL) and STATA 12.0 (StataCorp, College Station, TX). For all analyses, we set P < 0.05 of statistical significance.

RESULTS

KIF2A mRNA Expression in EOC by PCR

To evaluate the KIF2A mRNA expression between EOC and normal tissue, RNA was isolated from 15 cases of ovarian carcinoma and 10 normal ovary and 10 normal fallopian tube tissue samples using real-time PCR. As is shown in Figure 1, the means of KIF2A mRNA in carcinoma and in noncancerous tissues (ovary and fallopian tube) were 0.351 ± 0.203, 0.138 ± 0.068, and 0.125 ± 0.085, respectively. PCR results showed higher expression of KIF2A mRNA in ovarian cancer samples than in noncancerous tissues (all P < 0.05).

FIGURE 1. KIF2A mRNA expression in EOC tissues and normal tissues. Real-time PCR demonstrated that KIF2A mRNA expression in EOC, normal ovary, and normal fallopian tube tissues were 0.351 ± 0.203, 0.138 ± 0.068, and 0.125 ± 0.085, respectively. KIF2A mRNA expression in EOC samples was significantly higher than in normal ovarian tissue, fallopian tube tissue samples (all P < 0.05). EOC = epithelial ovarian cancer, KIF2A = Kinesin family member 2A.
KIF2A and HER2-Neu Protein Expression in EOC by IHC

IHC analysis was performed to detect KIF2A and HER2-neu in EOC tissue specimens using TMA. Positive staining of KIF2A was predominantly localized in the cytoplasm of EOC cells while HER2-neu was localized in the cytomembrane (Figure 2). Overexpression of KIF2A was observed in 71.17% (79/111) of EOC tumors, 16.67% (4/24) of normal ovarian samples, and 20.83% (5/24) of normal fallopian samples ($P < 0.01$). Overexpression of HER2-neu was observed in 31.53% (35/111) of EOC tumors, 8.33% (2/24) of normal ovarian samples, and 12.50% (3/24) of normal fallopian samples ($P < 0.01$). Chi-squared test analysis indicated that both KIF2A and HER2-neu expression were significantly upregulated in EOC samples, when compared with its general negative or low expression in normal ovarian and fallopian tube tissues ($P < 0.01$; Table 1). Interestingly, high KIF2A and HER2-neu coexpression (KIF2AH/HER2-neuH) were only detected in EOC patients, and none of normal ovarian or fallopian tissues had KIF2AH/HER2-neuH staining, although not all ovarian carcinoma show coexpression of KIF2A and HER2-neu.

Association Between KIF2A and HER2-Neu Expression and Clinicopathological Parameters of EOC

To clarify the potential prognostic roles of KIF2A alone or combined with HER2-neu in EOC development and progression, we evaluated the association of KIF2A and HER2-neu expression with various clinical features of EOC. Associations of KIF2A expression and clinicopathological factors are summarized in Table 2. While stratifying clinical characteristics by KIF2A expression (high vs low), we observed that high KIF2A (KIF2AH) protein expression was significantly associated with FIGO stages ($P = 0.002$), ascites cell ($P = 0.029$), metastasis ($P = 0.027$), and lymph nodes ($P = 0.047$; Table 2). However, there was no significant association observed between KIF2A expression and patients’ age, tumor grade, histological type, tumor single or double, level of CA-125, or HER2-neu expression level in the present study (Table 2). Moreover, HER2-neu expression alone showed a positive association with FIGO stages ($P = 0.001$), metastasis ($P = 0.048$), and level of CA-125 ($P < 0.017$). The trends...
toward its associations with remaining clinical characteristics did not reach statistical significance (Table 2). To test whether high HER2-neu expression (HER2-neuH) coupled with KIF2A\\(^H\) in the ovarian epithelium could identify a subgroup patients with a poor outcome, we further compared prognosis among patients with KIF2A\\(^H\)/HER2-neu\\(^H\) and non-KIF2A\\(^H\)/HER2-neu\\(^H\) (KIF2A\\(^L\)/HER2-neu\\(^L\), KIF2A\\(^H\)/HER2-neu\\(^L\), and KIF2A\\(^L\)/HER2-neu\\(^L\) phenotypes; ‘\\(^H\)’ stands for high expression; ‘\\(^L\)’ stands for low or no expression). We found that simultaneously high KIF2A and HER2-neu expression were significantly related to survival, and invasion. To better understand the potential roles of KIF2A, we hypothesized that aberrant KIF2A and HER2-neu expression might be associated with aggressive behavior of EOC. We determined the association of KIF2A and HER2-neu expression levels, or a combination of both protein markers with OS in patients with EOC. In this study, we found that the expression level of mitotic centromere-associated Kinesin-13 protein KIF2A was elevated in EOC. The increase in KIF2A expression was associated with a decreased survival time in EOC patient, indicating that KIF2A might be a potential prognosis biomarker for EOC. We also demonstrated that patients with advanced FIGO stage disease and metastasis had more frequent high KIF2A expression in contrast those in the early stage of the disease. These findings suggest that high KIF2A expression may promote tumor progression and metastasis and that KIF2A may be used as a potential biomarker to identify a subgroup with more aggressive phenotype of EOC.

There are 3 distinct genes that encode the Kinesin-13 family members in the human genome, including KIF2A (chromosome 5q12), KIF2B (chromosome 17q22), and MCAK/KIF2C (chromosome 1p34). These protein products of these genes participate in intracellular transport, cell division, and bipolar spindle assembly during spindles formation. While cancer cells undergo continuous cell division, incessant chromosomal missegregation may cause the chromosome to lose stability during mitosis. The KIFs are involved in spindle orientation and chromosomal movements during mitosis and cytoskeletal reorganization. It has been shown that KIF2A, essential for bipolar spindle assembly and chromosome movement, is able to depolymerize microtubule in vitro. KIF2A localizes to spindle poles in human cells. Cells lacking KIF2A fail to form bipolar spindle, but form monopolar in mitosis, leading to arrest of cell cycle progression. Monopolar spindles in the cells could cause the gain or loss of chromosomes in daughter cells. Any “error” in this process may cause chromosome missegregation, leading to substantial alteration in cell proliferation and migration. Previous studies on KIF2A demonstrated that KIF2A silencing induces apoptosis of human oral squamous cell carcinoma Tca-8113 cell lines. Moreover, several lines of evidence showed that KIF2A is an upstream inducer of PI3K/AKT pathway, and therefore, it is meaningful to inhibit PI3K/AKT pathway.
TABLE 2. Patient Clinicopathological Characteristics According to KIF2A/HER2-Neu Scores

| Groups | n = 111 | KIF2A HER2-Neu | KIF2A/HER2-Neu |
|--------|---------|----------------|---------------|
|        |         | High Expression | Pearson | P Value | High Expression | Pearson | P Value | Non-KIF2A\(^H\)/HER2-neu\(^H\) | Pearson | P Value |
| Age at diagnosis, y |       |               |         |         |               |         |         |                                 |         |         |
| ≤60     | 77      | 52 (67.53)     | 1.622   | 0.203   | 23 (29.87)     | 0.321   | 0.571   | 59 (76.62)                         | 0.455   | 0.500   |
| >60     | 34      | 27 (79.41)     | 2.484   | 0.115   | 12 (35.29)     | 3.568   | 0.059   | 24 (70.59)                         | 3.385   | 0.066   |
| Grade   |         |               |         |         |               |         |         |                                 |         |         |
| Low     | 21      | 12 (57.14)     | 0.057   | 0.812   | 3 (14.29)      | 1.476   | 0.224   | 19 (90.48)                         | 0.363   | 0.547   |
| High    | 90      | 67 (74.44)     |         |         | 32 (35.56)     |         |         | 64 (71.11)                         |         |         |
| Single  |         |               |         |         |               |         |         |                                 |         |         |
| or double Single | 54      | 39 (72.22)     | 0.011   | 0.916   | 20 (37.04)     | 2.799   | 0.094   | 39 (72.22)                         | 6.005   | 0.014*  |
| Double  | 57      | 40 (70.18)     |         |         | 15 (26.32)     |         |         | 44 (77.19)                         |         |         |
| Type    |         |               |         |         |               |         |         |                                 |         |         |
| Serous  | 84      | 60 (71.43)     | 3.948   | 0.047*  | 20 (25.00)     | 1.420   | 0.233   | 64 (80.00)                         | 1.501   | 0.221   |
| Other\(^1\) | 27      | 19 (70.37)     |         |         | 5 (18.52)      |         |         | 25 (92.59)                         |         |         |
| Lymph nodes |         |               |         |         |               |         |         |                                 |         |         |
| No      | 80      | 52 (65.00)     | 4.907   | 0.027*  | 11 (21.15)     | 3.919   | 0.048   | 44 (84.62)                         | 4.701   | 0.030*  |
| Yes     | 18      | 16 (88.89)     |         |         | 7 (38.89)      |         |         | 12 (66.67)                         |         |         |
| Unknown | 13      | 11             |         |         | 8             |         |         | 7                                  |         |         |
| Metastasis\(^z\) |         |               |         |         |               |         |         |                                 |         |         |
| No      | 52      | 32 (61.54)     | 4.771   | 0.029*  | 13 (24.53)     | 0.482   | 0.488   | 43 (81.13)                         | 0.831   | 0.362   |
| Yes     | 57      | 46 (80.70)     |         |         | 8 (32.00)      |         |         | 18 (72.00)                         |         |         |
| Unknown | 2       | 1              |         |         | 14            |         |         | 22                                  |         |         |
| FIGO stage |         |               |         |         |               |         |         |                                 |         |         |
| 1       | 51      | 29 (56.86)     | 9.414   | 0.002*  | 6 (11.76)      | 17.076  | 0.001*  | 47 (92.16)                         | 15.113  | 0.001*  |
| 2–4     | 60      | 50 (83.33)     |         |         | 29 (48.33)     | 5.697   | 0.017*  | 36 (60.00)                         | 4.521   | 0.033*  |
| Preoperative serum |         |               |         |         |               |         |         |                                 |         |         |
| CA-125, U/mL |         |               |         |         |               |         |         |                                 |         |         |
| 0       | 9       | 7 (77.78)      | 0.004   | 0.948   | 0 (0.00)       | 5.697   | 0.017*  | 9 (100.00)                         | 4.521   | 0.033*  |
| 1       | 69      | 53 (76.81)     |         |         | 28 (40.58)     |         |         | 45 (65.22)                         |         |         |
| Unknown | 33      | 19             |         |         | 7             |         |         | 29                                  |         |         |
| HER2-neu |         |               |         |         |               |         |         |                                 |         |         |
| Low     | 76      | 52 (68.42)     | 0.889   | 0.346   | 76 (100.00)    | 8.131   | 0.001*  | 7 (20.00)                          |         |         |
| High    | 35      | 27 (77.14)     |         |         | 29            |         |         | 11.643                              |         |         |
| KIF2A   |         |               |         |         |               |         |         |                                 |         |         |
| Low     | 32      | 8 (25.00)      | 0.889   | 0.346   | 31 (96.88)     | 11.643  | 0.001*  | 52 (65.82)                         |         |         |
| High    | 79      | 27 (34.18)     |         |         | 24            |         |         | 52 (65.82)                         |         |         |

Superscript “\(^H\)” stands for high expression, superscript “\(^L\)” stands for low or no expression.

HER2-neu = human epidermal growth factor receptor 2, KIF2A = Kinesin family member 2A.

\(^1\) Endometrioid carcinoma, 21 cases; clear cell carcinoma, 2 cases; mucinous carcinoma, 4 cases; transitional cell carcinoma, 1 case; adeno-squamous carcinoma, 1 case.

\(^z\) Pelvic lymph node metastases or nearby tissues and organs involved.

\(^*\) P < 0.05 indicates a significant association among the variables.
AKT by KIF2A silencing since the over activation of PI3K/AKT is a frequent event in various human cancer.32–34 The PI3K/AKT pathway plays a key role in regulating multiple important cellular activities including proliferation, survival, and differentiation.35 PI3K/AKT signaling pathway has been extensively investigated as a target for cancer therapy, due to its functions in regulating cell cycle control, driving carcinogenesis, and imparting chemoresistance to anticancer treatment.36 A number of candidate drugs targeting this pathway have been discovered and entered clinical trials, such as inhibitors of PI3K, epidermal growth factor receptor (PDGF-R), and mammalian target of rapamycin (mTOR), as well as monoclonal HER2-neu antibody.

HER2-neu, the ERBB2 proto-oncogene encodes a transmembrane protein tyrosine kinase receptor, which are involved in the occurrence and development of many types of cancers, including ovarian cancer.37 Dysregulated HER2-neu signaling in EOC results from either gene amplification or overexpression, which leads to faster cell growth, DNA damage, and increased colony formation.38 The PI3K/AKT pathway is a major downstream signaling pathway of HER2-neu. Studies have shown that the addition of PI3K/AKT inhibitors to treatments for patients with HER2-neu-positive tumors and PI3K pathway activation may increase their response to HER2-neu blockade and improve clinical outcomes.39 Activation of the PI3K/AKT pathway has been implicated in resistance to anticancer therapies, including chemotherapy, endocrine therapy, and HER2-neu-targeted therapy, and blocking PI3K/AKT pathway signaling may be able to enhance efficacy of these therapies.38 In this study, the results showed that both positive KIF2A and HER2-neu staining was significantly related to FIGO stage, though we did not detect correlation between KIF2A and HER2-neu expression. The level of KIF2A expression was strongly associated with an increased risk of metastasis and poor overall survival outcomes. These data indicated that increased KIF2A expression correlated with invasive behavior and metastatic processes of EOC. Both univariate and multivariate analyses demonstrated that KIF2A and HER2-neu expression appeared to be an independent prognostic factor for OS in patients with EOC.

Despite some limitations, such as the small number of patients and relatively short follow-up time, our results provide the first evidence that KIF2A might be used as a novel biomarker to identify EOC patients with “poor diagnosis” after surgery and ameliorate personalized medicine. Our analysis showed that level of KIF2A and HER2-neu is elevated in EOC patients with tumors that had both PIK3CA mutation and PTGS2 expression respond best to aspirin therapy.39 Additional research would be required to confirm our findings.

In conclusion, this study may advance our understanding of the role of KIF2A in the progression and development of EOC. Further studies are needed to investigate related signaling pathways such as PI3K/AKT pathway and potential mechanisms underlying the oncogenic impact of KIF2A overexpression in EOC, which may help to fully understand and exploit the prognostic and therapeutic value of KIF2A.

### Table 3. Univariate and Multivariate Cox Proportional Hazard Models of Overall Survival

| Variables                      | Univariate Analysis | Multivariate Analysis |
|--------------------------------|---------------------|-----------------------|
|                                | HR                  | P         | 95% CI | HR     | P         | 95% CI  |
| KIF2A expression               |                     |           |        |        |           |        |
| Low vs high                    | 0.200               | 0.001*    | 0.086–0.466 | 0.437 | 0.007*    | 0.241–0.795 |
| HER2-neu expression            |                     |           |        |        |           |        |
| Low vs high                    | 0.476               | 0.005*    | 0.282–0.803 | 0.522 | 0.017*    | 0.307–0.890 |
| KIF2A/HER2-neu expression      |                     |           |        |        |           |        |
| KIF2A+/HER2-neu+ vs non-KIF2A+/HER2-neu+ | 0.426 | 0.002* | 0.248–0.733 | 3.048 | 0.199 | 0.577–16.680 |
| Age, y                         |                     |           |        |        |           |        |
| <60 vs ≥60                     | 0.476               | 0.006*    | 0.281–0.809 | 0.354 | 0.214 | 0.069–1.823 |
| FIGO stage                     |                     |           |        |        |           |        |
| I vs II–IV                     | 0.230               | 0.001*    | 0.127–0.417 | 0.287 | 0.001*    | 0.151–0.545 |
| Grade                          |                     |           |        |        |           |        |
| Low vs high                    | 0.462               | 0.055     | 0.210–1.017 |        |        |          |
| Single or double               |                     |           |        |        |           |        |
| Single vs double               | 1.352               | 0.246     | 0.812–2.249 |        |        |          |
| Histological type              |                     |           |        |        |           |        |
| Serous vs others               | 1.501               | 0.209     | 0.797–2.827 |        |        |          |

Superscript “H” stands for high expression and superscript “L” stands for low or no expression. CI = confidence interval, HER2-neu = human epidermal growth factor receptor 2, HR = hazard ratio, KIF2A = Kinesin family member 2A. *P < 0.05.
REFERENCES

1. Zhang B, Cai FF, Zhong XY. An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol. 2011;158:119–123.

2. Corney DC, Hwang CI, Matoso A, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res. 2010;16:1119–1128.

3. Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther. 2010;9:1931–1944.

4. Kelly K, Huang C. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. J Thorac Oncol. 2008;3:664–673.

5. Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res. 2012;18:619–624.

6. Wang CQ, Qu X, Zhang XY, et al. Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongue. Oral Oncol. 2010;46:65–69.

7. Wang K, Lin C, Wang C, et al. Silencing Kif2a induces apoptosis in squamous cell carcinoma of the oral tongue through inhibition of the PI3K/Akt signaling pathway. Mol Med Rep. 2014;9:273–278.

8. Lanitis E, Dangaj D, Hagemann IS, et al. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS ONE. 2012;7:e49829.

9. Abraham J. PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? Expert Rev Anticancer Ther. 2015;15:51–68.

10. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–1529.

11. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673–684.
12. Bartsch R, Wenzel C, Zielinski CC, et al. HER-2-positive breast cancer: hope beyond trastuzumab. *BioDrugs*. 2007;21:69–77.

13. Han L, Jiang B, Wu H, et al. High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma. *Med Oncol*. 2012;29:2466–2472.

14. Fan X, Wang X, Zhu H, et al. KIF2A overexpression and its association with clinicopathologic characteristics and unfavorable prognosis in colorectal cancer. *Tumour Biol*. 2015;36:8895–8902.

15. Xu Y, Wang C, Zhang Y, et al. Overexpression of MAGE-A9 is predictive of poor prognosis in epithelial ovarian cancer. *Sci Rep*. 2015;5:12104.

16. Sun R, Wang X, Zhu H, et al. Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues. *Oncotarget*. 2014;5:12398–12409.

17. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res*. 2004;10:7252–7259.

18. Wang J, Ma S, Ma R, et al. KIF2A silencing inhibits the proliferation and migration of breast cancer cells and correlates with unfavorable prognosis in breast cancer. *BMC Cancer*. 2014;14:461.

19. Zhang Q, Zhang W, Zhang J, et al. Aberrant Kif2a and Ki67 expression predicts poor survival in laryngeal squamous cell carcinoma. *Auris Nasus Larynx*. 2015.

20. Manning AL, Ganem NJ, Bakhoum SF, et al. The Kinesin-13 proteins Kif2a, Kif2b, and Kif2c/MCAK have distinct roles during mitosis in human cells. *Mol Biol Cell*. 2007;18:2970–2979.

21. Wittmann T, Hyman A, Desai A. The spindle: a dynamic assembly of microtubules and motors. *Nat Cell Biol*. 2001;3:E28–E34.

22. Shimo A, Tanikawa C, Nishidate T, et al. Involvement of Kinesin family member 2C/mitotic centromere-associated Kinesin overexpression in mammary carcinogenesis. *Cancer Sci*. 2008;99:62–70.

23. Homma N, Takei Y, Tanaka Y, et al. Kinesin superfamily protein 2A (KIF2A) functions in suppression of collateral branch extension. *Cell*. 2003;114:229–239.

24. Hirokawa N, Noda Y, Okada Y. Kinesin and dynein superfamily proteins in organelle transport and cell division. *Curr Opin Cell Biol*. 1998;10:60–73.

25. Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. *Nature*. 2000;407:41–47.

26. Ganem NJ, Compton DA. The KinI kinesin Kif2a is required for bipolar spindle assembly through a functional relationship with MCAK. *J Cell Biol*. 2004;166:473–478.

27. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. *Tumori*. 2004;90:2–8.

28. Yen CC, Chen YJ, Lu KH, et al. Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction. *Int J Oncol*. 2003;23:871–881.

29. Nguyen TD, Dang NG, Tran TT, et al. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. *Cancer Res*. 2009;69:5918–5926.

30. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in head and neck squamous cell carcinoma. *Oncogene*. 2009;28:4683–4689.

31. Ishikawa K, Kamohara Y, Tanaka F, et al. Mitotic centromere-associated Kinesin is a novel marker for prognosis and lymph node metastasis in colorectal cancer. *Br J Cancer*. 2008;98:1824–1829.

32. Vale RD, Fletterick RJ. The design plan of Kinesin motors. *Annu Rev Cell Dev Biol*. 1997;13:745–777.